Early genetic testing > early genetic testing pregnancy > Ninalia NIPT

NIPT by Biomnis The new prenatal trisomy screening test based on maternal blood sample

Trisomy 13

Download the brochure

Early genetic testing

For Women With High-Risk Pregnancies, Early Genetic Testing is Key

Learning that you are expecting a baby is one of life's most joyous momentsâ€but it can also cause anxiety when you learn that your pregnancy is considered a high-risk one. Women with heightened pregnancy risks routinely undergo early genetic testing to rule out disorders including Down Syndrome. As an alternative to invasive procedures such as amniocentesis, which carry a small risk of loss of the fetus, Eurofins Biomnis offers non-invasive prenatal testing of trisomy 21 and other anomalies. The test draws analysis from a simple maternal blood sample, and offers over 99% accuracy. By opting for this early genetic testing option, risks of chromosomal defects can be screened early.

Although most expectant parents are aware of risks for fetal genetic defects, and wonder whether disorders such as Patau Syndrome can be detected, many people are unaware that early genetic testing during pregnancy needs not be invasive. Thanks to groundbreaking efforts from researchers, effective and safe non-invasive testing methods are now readily available. Reliable and rapid, the test can be obtained starting in only the tenth week of pregnancy. It simultaneously detects risks for trisomies 13, 18 and 21â€offering peace of mind from earlier on. Explore the website to learn more about why non-invasive early genetic testing during pregnancy may be the right option for you.

When it comes to genetic disease testing, it can be easy to assume that early genetic and gender testing must be at least as complicated as traditional, invasive procedures such as amniocentesis. However, the testing kit developed byEurofins Biomnis is remarkably simple to administer. It can be prescribed by your regular healthcare provider, and you can have the blood test taken at your physician's office or at a Eurofins Biomnis partner laboratory. With results of the blood test available in around 7 working days, NIPT by Eurofins Biomnis is a risk-free form ofnon-invasive early genetic and gender testing. It has been found to reduce unnecessary invasive sampling by up to 95%.

Advantages of NIPT by Biomnis

> 99 % Detection rateof NIPT test 1 Single blood sample 10 Available from week 10of amenorrhoea 7 Results availablewithin 7 working days 95 % Can minimize unnecessary invasive sampling by 95%